ARV/ART

Thumbnail for Module 16. Hepatic Coinfection

Hepatitis B and hepatitis C are common coinfections in HIV+ patients. Liver disease related to these infections is a frequent cause of mortality in coinfected patients.

Thumbnail for Module 15. Neurologic Complications

An array of neurologic complications may be caused by, or affected by the HIV virus and its treatment. These issues can impact choice and timing of antiretroviral therapy.

Thumbnail for Module 14. CV Complications of HIV

The HIV+ population exhibits a higher prevalence of traditional cardiovascular risk factors, including smoking, poor diet, sedentary lifestyle, substance abuse, stress, and mental illness.

Thumbnail for Module 13. Bone Complications of HIV

HIV+ persons are at higher risk for bone loss and subsequent fractures than uninfected persons. Demographic, lifestyle, HIV-specific, and ART-specific risk factors contribute to bone loss.

Thumbnail for Module 12. Renal Comorbidity

Understanding the epidemiology and risk factors for renal disease in HIV+ patients helps clinicians distinguish among a broad spectrum of renal diseases in this population.

Thumbnail for Module 6. Classes of ARV Medications

A complete ARV regimen combines drugs targeting different steps in the HIV lifecycle. Guideline committees examine evidence to recommend first-line and later treatment.

Thumbnail for Module 5. Overview of ARV Therapy

Antiretroviral therapy (ART) has evolved greatly in the thirty-years since its inception from a single toxic agent to highly tolerable, highly effective, triple-drug therapy.

Knowledge Gaps Need to Be Addressed for Optimal ART Uptake in Women

  • May 30, 17
  • vin@gaugemedical.com
  • 0 Comments

A randomized control trial assessed HIV knowledge, treatment, beliefs and attitude of women who had previously received PMTCT (prevention-of-mother-to-child-transmission) [PMTCT] and were about to commence ART.

Read more

Starting Antiretroviral Treatment Early Improves Outcomes for HIV-Infected Individuals

  • May 30, 15
  • vin@gaugemedical.com
  • 0 Comments

A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune system health—is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV.

Read more

Diminished Physical Function in Older HIV+ Adults Despite Successful Antiretroviral Therapy

  • Aug 26, 14
  • vin@gaugemedical.com
  • 0 Comments

“More than 50% of HIV-infected adults in the US will be >50 years old in 2015……There is growing concern among patients and healthcare providers that this group is experiencing a premature or ‘accelerated aging’ process……We determined that HIV-infected older adults on effective ART (with suppressed HIV-1 viral loads) had diminished physical performance results when compared to normal reference controls…..Physical function was significantly diminished in older HIV+ persons when compared to reference standards for HIV- age/gender-matched controls. The magnitude of differences observed may be associated with poorer health, more disabilities, longer hospital stays, and higher costs, thus warranting intervention.”

Read more

Connect

Phone: 202-659-0699
Fax: 202-659-0976

Contact

AAHIVM National Office
1705 DeSales Street NW, Suite 700
Washington, D.C. 20036

About

The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.